Concepedia
Statistics
Publications
24
Citations
3.2K
H-Index
18
Active since
1988
Affiliations
Seoul National University Hospital(Current)
The University of Texas MD Anderson Cancer Center
Merck & Co., Inc., Rahway, NJ, USA (United States)
Princess Margaret Cancer Centre
Mayo Clinic in Arizona
Samuel Ejadi is an author at Seoul National University Hospital specializing in oncology, medicine, and cancer immunotherapy.
Publications per year
1988–2020
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad et al. · British Journal of Cancer · 2020 · 912 citations · Full text
Medicine, Oncology, Pharmacology +13
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 471 citations
Pharmacy, Oncology, Pharmacotherapy +17
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Aaron R. Hansen, Christophe Massard, Patrick A. Ott et al. · Annals of Oncology · 2018 · 367 citations
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text
Medicine, Oncology, Pharmacology +17
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster et al. · Annals of Oncology · 2017 · 253 citations · Full text
1–5 of 24